Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.
Bowyer, S Prithviraj, P Lorigan, Paul C Larkin, J McArthur, G Atkinson, V Millward, M Khou, M Diem, S Ramanujam, S
Bowyer, S
Prithviraj, P
Lorigan, Paul C
Larkin, J
McArthur, G
Atkinson, V
Millward, M
Khou, M
Diem, S
Ramanujam, S
Citations
Altmetric:
Abstract
Recent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and nivolumab over the anti-CTLA-4 antibody ipilimumab in the first-line treatment of patients with advanced melanoma. Ipilimumab will be considered for second-line treatment after the failure of anti-PD-1 therapy.
Description
Date
2016-05-10
Publisher
Collections
Keywords
Type
Article
Citation
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. 2016, 114 (10):1084-9 Br J Cancer